Irbesartan: A Review of its Use in Hypertension and Diabetic Nephropathy

Authors: Croom, Katherine F.; Plosker, Greg L.

Source: Drugs, Volume 68, Number 11, 2008 , pp. 1543-1569(27)

Buy & download fulltext article:

Price: $68.55 plus tax (Refund Policy)

Abstract:

Irbesartan (Aprovel^®, Avapro^®, Irbetan^®, Karvea^®), an angiotensin II receptor type 1 antagonist, is approved in many countries worldwide for the treatment of hypertension. It is also approved in some regions for the treatment of nephropathy in patients with hypertension and type 2 diabetes mellitus. In adults with essential hypertension, irbesartan is effective at reducing blood pressure (BP) over a 24-hour period with once-daily administration. Irbesartan also slows the progression of renal disease in hypertensive patients with type 2 diabetes, with this effect partly independent of its BP-lowering effect. In addition, irbesartan was generally well tolerated in clinical trials. Thus, irbesartan is a useful treatment option for patients with hypertension, including those with type 2 diabetes and nephropathy.

Keywords: Adis Drug Evaluations; Diabetic nephropathies; Hypertension; Irbesartan

Document Type: Research article

Affiliations: 1: Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

Publication date: 2008-01-01